Aimmune Therapeutics Inc. (AIMT) Insider Mary M. Rozenman Sells 25,000 Shares of Stock
Aimmune Therapeutics Inc. (NASDAQ:AIMT) insider Mary M. Rozenman sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, October 5th. The stock was sold at an average price of $16.80, for a total transaction of $420,000.00. Following the completion of the sale, the insider now owns 25,000 shares of the company’s stock, valued at approximately $420,000. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) opened at 16.55 on Friday. The company’s market cap is $699.30 million. Aimmune Therapeutics Inc. has a one year low of $9.77 and a one year high of $22.01. The company’s 50-day moving average is $15.53 and its 200-day moving average is $13.65.
Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Wednesday, August 10th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.01. On average, equities analysts predict that Aimmune Therapeutics Inc. will post ($1.75) EPS for the current year.
Several large investors have recently added to or reduced their stakes in AIMT. Metropolitan Life Insurance Co. NY raised its stake in Aimmune Therapeutics by 9.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 9,617 shares of the company’s stock worth $130,000 after buying an additional 797 shares during the last quarter. Emerald Acquisition Ltd. acquired a new stake in Aimmune Therapeutics during the second quarter worth about $154,000. American International Group Inc. raised its stake in Aimmune Therapeutics by 135.7% in the second quarter. American International Group Inc. now owns 15,131 shares of the company’s stock worth $164,000 after buying an additional 8,711 shares during the last quarter. Nationwide Fund Advisors raised its stake in Aimmune Therapeutics by 127.7% in the second quarter. Nationwide Fund Advisors now owns 16,929 shares of the company’s stock worth $183,000 after buying an additional 9,495 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new stake in Aimmune Therapeutics during the second quarter worth about $186,000. 68.87% of the stock is owned by institutional investors and hedge funds.
Several research firms have recently issued reports on AIMT. Wedbush restated an “outperform” rating and issued a $42.00 target price on shares of Aimmune Therapeutics in a report on Monday, June 13th. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 26th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $38.00 price objective on shares of Aimmune Therapeutics in a report on Tuesday, June 14th. JMP Securities initiated coverage on shares of Aimmune Therapeutics in a report on Monday, September 26th. They set an “outperform” rating and a $30.00 price objective for the company. Finally, Credit Suisse Group AG reiterated a “buy” rating and set a $35.00 price objective on shares of Aimmune Therapeutics in a report on Friday, August 19th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Aimmune Therapeutics has an average rating of “Buy” and a consensus price target of $32.20.
About Aimmune Therapeutics
Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Stock Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related stocks with our FREE daily email newsletter.